Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SP 2 225

Next Previous
Drug Profile

SP 2 225

Alternative Names: SP-2-225

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shuttle Pharmaceuticals
  • Class Amides; Amines; Antineoplastics; Biphenyl compounds; Hexanes; Radiation-sensitising agents; Small molecules
  • Mechanism of Action HDAC6 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Lung cancer; Multiple myeloma
  • No development reported Malignant melanoma

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (Intraperitoneal)
  • 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Malignant melanoma presented at 115th Annual Meeting of the American Association for Cancer Research (AACR-2024 2024)
  • 11 Sep 2023 Shuttle Pharmaceuticals receives a issuance of a Canadian patent for its histone deacetylase (HDAC) inhibitor platform

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top